NCT04382547View on ClinicalTrials.gov

Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 11, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
COVIDCovid-19CoronavirusPneumoniaPneumonia, ViralPneumonia, InterstitialSars-CoV2
Interventions
BIOLOGICAL

Allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Allogenic pooled olfactory mucosa-derived mesenchymal stem cells

OTHER

Standard treatment according to the Clinical protocols

Standard treatment according to the Clinical protocols

Trial Locations (1)

220072

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk

All Listed Sponsors
collaborator

Belarusian State Medical University

OTHER

lead

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

OTHER_GOV

NCT04382547 - Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells | Biotech Hunter | Biotech Hunter